Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models.

Rivera-Munoz P, Laurent AP, Siret A, Lopez CK, Ignacimouttou C, Cornejo MG, Bawa O, Rameau P, Bernard OA, Dessen P, Gilliland GD, Mercher T, Malinge S.

Blood Adv. 2018 Jul 10;2(13):1616-1627. doi: 10.1182/bloodadvances.2018016089.

2.

Molecular pathways driven by ETO2-GLIS2 in aggressive pediatric leukemia.

Thirant C, Lopez C, Malinge S, Mercher T.

Mol Cell Oncol. 2017 Sep 26;4(6):e1345351. doi: 10.1080/23723556.2017.1345351. eCollection 2017.

PMID:
29209645
3.

Pediatric Acute Megakaryoblastic Leukemia: Multitasking Fusion Proteins and Oncogenic Cooperations.

Lopez CK, Malinge S, Gaudry M, Bernard OA, Mercher T.

Trends Cancer. 2017 Sep;3(9):631-642. doi: 10.1016/j.trecan.2017.07.003. Epub 2017 Aug 18. Review.

PMID:
28867167
4.

The mitochondrial respiratory chain is essential for haematopoietic stem cell function.

Ansó E, Weinberg SE, Diebold LP, Thompson BJ, Malinge S, Schumacker PT, Liu X, Zhang Y, Shao Z, Steadman M, Marsh KM, Xu J, Crispino JD, Chandel NS.

Nat Cell Biol. 2017 Jun;19(6):614-625. doi: 10.1038/ncb3529. Epub 2017 May 15.

5.

ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia.

Thirant C, Ignacimouttou C, Lopez CK, Diop M, Le Mouël L, Thiollier C, Siret A, Dessen P, Aid Z, Rivière J, Rameau P, Lefebvre C, Khaled M, Leverger G, Ballerini P, Petit A, Raslova H, Carmichael CL, Kile BT, Soler E, Crispino JD, Wichmann C, Pflumio F, Schwaller J, Vainchenker W, Lobry C, Droin N, Bernard OA, Malinge S, Mercher T.

Cancer Cell. 2017 Mar 13;31(3):452-465. doi: 10.1016/j.ccell.2017.02.006.

6.

Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.

Wen QJ, Yang Q, Goldenson B, Malinge S, Lasho T, Schneider RK, Breyfogle LJ, Schultz R, Gilles L, Koppikar P, Abdel-Wahab O, Pardanani A, Stein B, Gurbuxani S, Mullally A, Levine RL, Tefferi A, Crispino JD.

Nat Med. 2015 Dec;21(12):1473-80. doi: 10.1038/nm.3995. Epub 2015 Nov 16.

7.

DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3.

Thompson BJ, Bhansali R, Diebold L, Cook DE, Stolzenburg L, Casagrande AS, Besson T, Leblond B, Désiré L, Malinge S, Crispino JD.

J Exp Med. 2015 Jun 1;212(6):953-70. doi: 10.1084/jem.20150002. Epub 2015 May 25.

8.

Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation.

Lane AA, Chapuy B, Lin CY, Tivey T, Li H, Townsend EC, van Bodegom D, Day TA, Wu SC, Liu H, Yoda A, Alexe G, Schinzel AC, Sullivan TJ, Malinge S, Taylor JE, Stegmaier K, Jaffe JD, Bustin M, te Kronnie G, Izraeli S, Harris MH, Stevenson KE, Neuberg D, Silverman LB, Sallan SE, Bradner JE, Hahn WC, Crispino JD, Pellman D, Weinstock DM.

Nat Genet. 2014 Jun;46(6):618-23. doi: 10.1038/ng.2949. Epub 2014 Apr 20.

9.

Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes.

Malinge S, Chlon T, Doré LC, Ketterling RP, Tallman MS, Paietta E, Gamis AS, Taub JW, Chou ST, Weiss MJ, Crispino JD, Figueroa ME.

Blood. 2013 Oct 3;122(14):e33-43. doi: 10.1182/blood-2013-05-503011. Epub 2013 Aug 26.

10.

Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling.

Malinge S, Thiollier C, Chlon TM, Doré LC, Diebold L, Bluteau O, Mabialah V, Vainchenker W, Dessen P, Winandy S, Mercher T, Crispino JD.

Blood. 2013 Mar 28;121(13):2440-51. doi: 10.1182/blood-2012-08-450627. Epub 2013 Jan 18.

11.

Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.

Malinge S, Bliss-Moreau M, Kirsammer G, Diebold L, Chlon T, Gurbuxani S, Crispino JD.

J Clin Invest. 2012 Mar;122(3):948-62. doi: 10.1172/JCI60455. Epub 2012 Feb 22.

12.

Myeloid leukemia in Down syndrome.

Khan I, Malinge S, Crispino J.

Crit Rev Oncog. 2011;16(1-2):25-36. Review.

13.

Notch: of mice and men?

Malinge S, Crispino J.

Blood. 2010 Dec 16;116(25):5438-9. doi: 10.1182/blood-2010-09-308395. No abstract available.

14.

Mutational analysis of candidate tumor-associated genes in acute megakaryoblastic leukemia.

Bhat R, Malinge S, Gamis AS, Sorrell AD, Hilden JM, Ketterling RP, Paietta E, Tallman MS, Crispino JD.

Leukemia. 2009 Nov;23(11):2159-60. doi: 10.1038/leu.2009.159. Epub 2009 Aug 6. No abstract available.

PMID:
19657363
15.

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL.

Blood. 2009 Jul 2;114(1):144-7. doi: 10.1182/blood-2009-03-210039. Epub 2009 May 6.

16.

Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome.

Malinge S, Izraeli S, Crispino JD.

Blood. 2009 Mar 19;113(12):2619-28. doi: 10.1182/blood-2008-11-163501. Epub 2009 Jan 12. Review.

17.

Activating mutations in human acute megakaryoblastic leukemia.

Malinge S, Ragu C, Della-Valle V, Pisani D, Constantinescu SN, Perez C, Villeval JL, Reinhardt D, Landman-Parker J, Michaux L, Dastugue N, Baruchel A, Vainchenker W, Bourquin JP, Penard-Lacronique V, Bernard OA.

Blood. 2008 Nov 15;112(10):4220-6. doi: 10.1182/blood-2008-01-136366. Epub 2008 Aug 28.

18.

Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.

Malinge S, Ben-Abdelali R, Settegrana C, Radford-Weiss I, Debre M, Beldjord K, Macintyre EA, Villeval JL, Vainchenker W, Berger R, Bernard OA, Delabesse E, Penard-Lacronique V.

Blood. 2007 Mar 1;109(5):2202-4. Epub 2006 Oct 26.

19.

Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotype.

Bardet V, Costa LD, Elie C, Malinge S, Demur C, Tamburini J, Lefebvre PC, Witz F, Lioure B, Jourdan E, Pigneux A, Ifrah N, Attal M, Dreyfus F, Mayeux P, Lacombe C, Bennaceur-Griscelli A, Bernard OA, Bouscary D, Récher C; GOELAMS: Groupe Ouest Est d'etude des Leucémies et des Autres Maladies du Sang.

Leukemia. 2006 Sep;20(9):1644-6. Epub 2006 Jun 22. No abstract available.

PMID:
16791266
20.

Supplemental Content

Loading ...
Support Center